JO
INDP icon

John Overdeck’s Indaptus Therapeutics INDP Stock Holding History

John Overdeck’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-14
Closed -$23K – 3800
2019
Q3 		$23K Sell
14
-36
-72% -$107K ﹤0.01% 3380
2019
Q2 		$491K Buy
+50
New +$631K ﹤0.01% 2515

Other funds holding INDP

MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

John Overdeck's INDP Position: Q4 2019 in Review

John Overdeck sold out of Indaptus Therapeutics (INDP) in Q4 2019, closing a stake of 14 shares — an estimated $23K sold.

John Overdeck first reported a position in INDP in Q2 2019 and held it in 2 quarters. The position peaked at $491K in Q2 2019. 25 funds tracked by Wall St. Rank hold INDP as of Q4 2019.

  • John Overdeck reported no remaining Indaptus Therapeutics position as of Q4 2019 after selling out during the quarter.
  • John Overdeck sold 14 Indaptus Therapeutics shares in Q4 2019, an estimated $23K.
  • John Overdeck first reported a position in Indaptus Therapeutics in Q2 2019 and held it in 2 quarters.
  • John Overdeck's Indaptus Therapeutics position peaked at $491K in Q2 2019.
  • 25 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q4 2019.

Based on Two Sigma Investments's 13F filing for Q4 2019, filed 14 Feb 2020.